Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-A3055 in advanced or metastatic solid tumors
NCT05935098Phase 1Terminated
- Sponsor
- BeiGene
- Start
- Aug 2023
- Primary completion
- Jan 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 5
01
Overview
Phase 1, open-label trial of BGB-A3055 in solid tumor (advanced stage) and metastatic solid tumor, sponsored by BeiGene. Primary endpoints: Number of participants with adverse events at 2 years, Maximum tolerated dose or maximum administered dose at 2 years and 2 more. Started Aug 2023; status: terminated.
02
Drugs
BGB-A3055
03
Conditions
solid tumor (advanced stage)metastatic solid tumor
Beyond the preview
Go deeper on NCT05935098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05935098.